Royal Bank of Canada
ELEV

Royal Bank of Canada’s Elevation Oncology ELEV Stock Holding History

Royal Bank of Canada’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,793
Closed -$1K – 7222
2025
Q2 		$1K Buy
1,793
+496
+38% +$166 ﹤0.01% 6874
2025
Q1 		$0 Sell
1,297
-3,225
-71% -$1.84K ﹤0.01% 6920
2024
Q4 		$3K Sell
4,522
-893
-16% -$527 ﹤0.01% 6636
2024
Q3 		$3K Buy
5,415
+508
+10% +$753 ﹤0.01% 6592
2024
Q2 		$13K Buy
+4,907
New +$18.5K ﹤0.01% 6236
2024
Q1 		– Sell
-370
Closed – – 7150
2023
Q4 		$0 Buy
370
+208
+128% +$110 ﹤0.01% 7237
2023
Q3 		$0 Sell
162
-197
-55% -$199 ﹤0.01% 7197
2023
Q2 		$1K Buy
+359
New +$947 ﹤0.01% 6990
2022
Q4 		– Sell
-169
Closed – – 7339
2022
Q3 		$0 Buy
+169
New +$213 ﹤0.01% 7538
2022
Q2 		– Sell
-60
Closed – – 7453
2022
Q1 		$0 Buy
+60
New +$241 ﹤0.01% 7802

Other funds holding ELEV

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Royal Bank of Canada's ELEV Position: Q3 2025 in Review

Royal Bank of Canada sold out of Elevation Oncology (ELEV) in Q3 2025, closing a stake of 1,793 shares — an estimated $1K sold.

Royal Bank of Canada first reported a position in ELEV in Q1 2022 and held it in 10 quarters. The position peaked at $13K in Q2 2024. 1 fund tracked by Wall St. Rank holds ELEV as of Q3 2025.

  • Royal Bank of Canada reported no remaining Elevation Oncology position as of Q3 2025 after selling out during the quarter.
  • Royal Bank of Canada sold 1,793 Elevation Oncology shares in Q3 2025, an estimated $1K.
  • Royal Bank of Canada first reported a position in Elevation Oncology in Q1 2022 and held it in 10 quarters.
  • Royal Bank of Canada's Elevation Oncology position peaked at $13K in Q2 2024.
  • 1 fund tracked by Wall St. Rank held Elevation Oncology as of Q3 2025.

Based on Royal Bank of Canada's 13F filing for Q3 2025, filed 14 Nov 2025.